Additional file 15 of Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Additional file 15: Supplementary Table 5. EC50 and EC90 values of capmatinib (cap), crizotinib (cri) and cabozantinib (cabo) following 3-day dose response assays. To calculate unbound EC50 and EC90 values, total values were multiplied with unbound drug fractions in culture media (Table 1).a, Scatter plots comparing differential gene expression analysis results from TRIM24-MET-i cells (upper panels) or TRIM24-MET-r cells (lower panels) treated with the depicted MET inhibitors in vitro (Cap - capmatinib; Cabo - cabozantinib; Cri – crizotinib; Veh - DMSO). Significant differentially expressed genes (adj. p < 0.05) for the x-axis comparison are colored orange, while those significantly differentially expressed in the y-axis comparison are colored purple. Green points are genes significantly differentially expressed in both comparisons. The number of unique and shared differentially expressed genes between each comparison are shown in parentheses. A linear regression line is depicted along with Pearson’s correlation coefficient (r) and its associated p-value. Open triangles indicate genes beyond the axis-limits. b, Bar plots showing significant (adj. p < 0.05) GSEA results for MSigDB Hallmark genesets for indicated cells and treatment comparisons (TRIM-MET cells were treated in vitro, TFG-MET cells in vivo). Common negatively enriched genesets between all three comparisons are in bold. c, Heatmaps showing expression of Hallmark_Myc_Target_v1/2 genes for indicated cells and treatment comparisons (TRIM-MET cells were treated in vitro, TFG-MET cells in vivo). Select leading edge genes from GSEA are labeled.